← TrialMatch
HomeTrials

Development of a Non-invasive Method for Quantifying Cerebral Glucose Metabolism for Study

The aim of the study is to develop a non-invasive method for quantifying cerebral glucose metabolism by PET scans in humans. This method will be used in subsequent studies, where the effect of the pancreatic hormone glucagon on cerebral glucose metabolism will be studied. The golden standard for quantifying cerebral gl

Condition(s)Cerebral Glucose Metabolism
StatusRecruiting
PhaseNA
Study typeInterventional
SummaryThe aim of the study is to develop a non-invasive method for quantifying cerebral glucose metabolism by PET scans in humans. This method will be used in subsequent studies, where the effect of the pancreatic hormone glucagon on cerebral glucose metabolism will be studied. The golden standard for quantifying cerebral glucose metabolism by PET scans is based on arterial blood sampling, which complicates research setup. This study will investigate if image derived measurements instead of arterial blood samples can be used to quantify cerebral glucose metabolism. We will compare the calculations of cerebral glucose metabolism based on arterial blood samples and image derived measurements and hopefully these will correlate. Healthy participants will be included, and each participant will partic
Who can participateInclusion Criteria: * Capable of understanding the participant information and signing the consent form * Between 25 and 70 years of age * Body mass index \<= 25 kg/m\^2 Exclusion Criteria: * Enrolment in other research project that might interfere with the study * Diabetes diagnosis * Pregnancy or breastfeeding * Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol * Diagnosis of psychiatric disorders, dementias, or any other neurological disorders that in the opinion of the investigator precludes compliance with the study protocol, evaluation of the results or represents an unacceptable risk for the participants safety * Severe claustrophobia * Cardiac problems including any of the following: 1. Classified as be
Ages25 Years to 70 Years
SexAll
Accepts healthy volunteersYes
Lead sponsorNicolai Jacob Wewer Albrechtsen
LocationsCopenhagen, Denmark
Start date2024-10-22
NCT IDNCT06647368
Official listinghttps://clinicaltrials.gov/study/NCT06647368

🔍 Search all trials →